Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejphar.2021.173934 http://scihub22266oqcxt.onion/10.1016/j.ejphar.2021.173934 33609563!ä!33609563 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Pharmacol 2021 ; 898 (ä): 173934 Nephropedia Template TP {{tp|p=33609563|t=2021. Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications |pdf=|usr=}}{{33609563}} gab.com Text Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications JO: Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33609563 #FOAvip Metformin is the most commonly prescribed oral antidiabetic medication. Direct/indirect activation of Adenosine Monophosphate-activated protein kinase (AMPK) and non-AMPK pathways, amongst others, are deemed to explain the molecular mechanisms of action of metformin. Metformin is an established insulin receptor sensitising antihyperglycemic agent, is highly affordable, and has superior safety and efficacy profiles. Emerging experimental and clinical evidence suggests that metformin has pleiotropic non-glycemic effects. Metformin appears to have weight stabilising, renoprotective, neuroprotective, cardio-vascular protective, and antineoplastic effects and mitigates polycystic ovarian syndrome. Anti-inflammatory and antioxidant effects of metformin seem to qualify it as an adjunct therapy in treating infectious diseases such as tuberculosis, viral hepatitis, and the current novel Covid-19 infections. So far, metformin is the only prescription medicine relevant to the emerging field of senotherapeutics. Non-glycemic effects of metformin favourable to its repurposing in therapeutic use are hereby discussed. Twit Text FOAVip Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications ????Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33609563 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33609563 #FOAvip English Wikipedia <ref>{{Cite pmid|33609563}}</ref> Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications #MMPMID33609563 Mbara KC; Mofo Mato PE; Driver C; Nzuza S; Mkhombo NT; Gcwensa SK; Mcobothi EN; Owira PM Eur J Pharmacol 2021[May]; 898 (ä): 173934 PMID33609563show ga Metformin is the most commonly prescribed oral antidiabetic medication. Direct/indirect activation of Adenosine Monophosphate-activated protein kinase (AMPK) and non-AMPK pathways, amongst others, are deemed to explain the molecular mechanisms of action of metformin. Metformin is an established insulin receptor sensitising antihyperglycemic agent, is highly affordable, and has superior safety and efficacy profiles. Emerging experimental and clinical evidence suggests that metformin has pleiotropic non-glycemic effects. Metformin appears to have weight stabilising, renoprotective, neuroprotective, cardio-vascular protective, and antineoplastic effects and mitigates polycystic ovarian syndrome. Anti-inflammatory and antioxidant effects of metformin seem to qualify it as an adjunct therapy in treating infectious diseases such as tuberculosis, viral hepatitis, and the current novel Covid-19 infections. So far, metformin is the only prescription medicine relevant to the emerging field of senotherapeutics. Non-glycemic effects of metformin favourable to its repurposing in therapeutic use are hereby discussed. |Animals[MESH] |Anti-Infective Agents/adverse effects/*therapeutic use[MESH] |Antineoplastic Agents/adverse effects/*therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/epidemiology[MESH] |Cardiovascular Diseases/prevention & control[MESH] |Female[MESH] |Humans[MESH] |Hypoglycemic Agents/adverse effects/*therapeutic use[MESH] |Immunologic Factors/adverse effects/*therapeutic use[MESH] |Kidney Diseases/prevention & control[MESH] |Metabolic Syndrome/drug therapy[MESH] |Metformin/adverse effects/*therapeutic use[MESH] |Obesity/drug therapy[MESH] |Pandemics[MESH] |Polycystic Ovary Syndrome/drug therapy[MESH] |Protective Agents/adverse effects/*therapeutic use[MESH]Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effe(epmc).pdf DeepDyve Pubget Overpricing